Process-Scale Precipitation of Impurities in Mammalian Cell Culture Broth - If certain engineering challenges can be addressed, precipitation may prove to be a valuable tool for antibody


Process-Scale Precipitation of Impurities in Mammalian Cell Culture Broth
If certain engineering challenges can be addressed, precipitation may prove to be a valuable tool for antibody purification

BioPharm International Supplements

Of particular interest are the numerous descriptions of the use of short-chain fatty acids, such as caprylic acid, for the precipitation of plasma proteins and DNA, as first described by Chanutin and Curnish in 1960.15 Several groups have developed conditions for the use of caprylic acid in antibody purification from various starting materials, such as ascites fluid and mammalian serum.16–19 Parkinnen and Lundblad also showed that caprylic acid could inactivate enveloped viruses.20,21

Evaluating Potential Precipitants for Impurity Removal


Table 1. Characteristics of the chemical compounds used in the precipitation evaluation
Using this large body of work as a guide, the Mammalian BioProcess Research and Development group at Pfizer, Inc. (New York, NY), recently completed an evaluation of several chemical compounds that could potentially be used to precipitate impurities from mammalian cell culture broth containing a MAb. Various cell culture broths from either Chinese hamster ovary (CHO) or NS0 cell lines were grown in an instrumented bioreactor from 1–10 liters in size. The chemical compounds discussed in this article are listed in Table 1.

The basic experimental protocol used for the evaluation was as follows: Cells and cellular debris were removed by centrifugation and depth filtration before the study commenced. The broth was adjusted to a final concentration of approximately 1 g antibody/L solution, the pH was adjusted, and the potential precipitant was added. The broth was incubated for 30–60 min, then pelleted in a Sorvall Evolution RC centrifuge for 10 min at 4,000g. The supernatant was separated from any precipitate, and if possible the precipitate was resolubilized. The resulting fractions of clarified supernatant and resolubilized precipitate were then tested for impurity levels using a standard Cygnus kit (Cygnus Technologies, Southport, NC) for HCP and the threshold assay for DNA. All of the precipitating agents were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO).

Ammonium Sulfate Precipitation

Ammonium sulfate precipitation for the purification of MAbs has been extensively documented in the literature.22–24 This method was performed and used as a standard comparison for antibody purity. In this case, the antibody was precipitated while the impurities remained in solution. After evaluating a range of ammonium sulfate concentrations, 1.8–2.0 M was chosen and tested for impurity removal and product yield at various pH values ranging from 4.0–7.0. The resulting precipitate was recovered by centrifugation and washed three times with ammonium sulfate solution to remove additional impurities. The precipitate was then resolubilized and analyzed.

Figure 1. Best results obtained from ammonium sulfate precipitation using a variety of NS0- and CHO-produced antibodies.
The best results obtained using a variety of NS0- and CHO-produced antibodies are shown graphically in Figure 1. The results indicate a 21-fold reduction in HCP (to 8,960 ng HCP/mg antibody) from the starting broth value, and a 79-fold reduction in DNA (to 38,800 pg DNA/mg antibody) with a yield of 91%. The fold reduction in impurities was calculated by dividing the impurity value in the broth by the impurity value in the antibody phase (supernatant or resolubilized precipitate, as appropriate).

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here